Latest Key Developments (Source: Significant Developments)

Dec 3 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 AND CONFIRMS DOSE FOR AMT-061 PIVOTAL STUDY IN HEMOPHILIA B.UNIQURE NV - CLINICAL BENEFIT OF AMT-060 MAINTAINED IN ALL PATIENTS THROUGH UP TO TWO AND A HALF YEARS OF FOLLOW-UP IN STUDY.UNIQURE NV - SECOND DOSE COHORT DEMONSTRATED A 93% REDUCTION IN FIX REPLACEMENT THERAPY USAGE DURING LAST TWELVE MONTHS OF OBSERVATION.UNIQURE NV - DOSE CONFIRMED FOR PHASE III PIVOTAL STUDY OF AMT-061, WITH PATIENT DOSING EXPECTED TO COMMENCE IN Q1 OF 2019.
Full Article

Oct 24 (Reuters) - Uniqure NV -:Uniqure announces pricing of its public offering.Uniqure NV says ‍announced pricing of its underwritten public offering of 5 million of its ordinary shares at a public offering price of $18.25 per share​.
Full Article

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: